A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions

Published:2019-05 Issue: Volume:109 Page:149-156
ISSN:0161-5890
Container-title:Molecular Immunology
language:en
Short-container-title:Molecular Immunology

Author:

Lu Li,Liu Ningbo,Fan Kaihu,Zhang Guojing,Li Chuan,Yan Yongjia,Liu Tong,Fu Wei-Huahua

Funder

Tianjin Health Institution Key Projects

Tianjin Medical University General Hospital Youth Incubation

Publisher

Elsevier BV

Subject

Molecular Biology,Immunology

Reference32 articles.

1. Sustained il-12 signaling is required for th1 development;Athiemorales;J. Immunol.,2004

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

3. Prognostic implications of altered human epidermal growth factor receptors (hers) in gastric carcinomas: her2 and her3 are predictors of poor outcome;Begnami;J. Clin. Oncology,2011

4. Bispecific antibody conjugates in therapeutics;Cao;Adv. Drug Deliv. Rev.,2003

5. Immune aspects of the breast tumor microenvironment;Chawla;Breast Cancer Manag.,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation CD40 agonists for cancer immunotherapy;Expert Opinion on Biological Therapy;2024-05-03

2. Advances in Therapeutic Targeting of the Tumor Necrosis Factor Receptor Superfamily Members for Cancer Immunotherapy;Handbook of Cancer and Immunology;2023

3. Correlation between childhood tuberculosis and abundance of T cell gene transcription and impaired T cell function;Tropical Journal of Pharmaceutical Research;2022-09-25

4. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer;Journal for ImmunoTherapy of Cancer;2022-07

5. An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies;Advanced Therapeutics;2022-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3